Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7181701

CCOC(C)Oc1ccc(PC(=O)c2c(C)cc(C)cc2C)c(C)c1.[Li]

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ TDP1 Q9NUW8 1/20 0.33
▸ ITGB1 P05556 1/20 0.33
▸ ITGA4 P13612 1/20 0.33
▸ TSPO P30536 2/20 0.33
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ PKM P14618 1/20 0.31
▸ HPGD P15428 3/20 0.31
▸ LMNA P02545 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ MCOLN3 Q8TDD5 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ FFAR1 O14842 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ ALDH1A1 P00352 2/20 0.30
▸ GAA P10253 2/20 0.30
▸ PPARG P37231 1/20 0.30
▸ PPARD Q03181 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7180677 0.91 SMN1; SMN2 (0.34) SMN1; SMN2TDP1MEN1KMT2APKM
Lithium SCHEMBL7175779 0.90 NR1H4 (0.32) SMN1; SMN2TDP1PPARGPPARDPPARA
SCHEMBL7189074 0.88 ITGB1 (0.32) SMN1; SMN2ITGB1ITGA4TSPOKDM4E
Lithium SCHEMBL7189179 0.88 SMN1; SMN2 (0.33) SMN1; SMN2TDP1MEN1KMT2APKM
Lithium SCHEMBL7177199 0.88 TDP1 (0.36) SMN1; SMN2TDP1ITGB1ITGA4TSPO
Lithium SCHEMBL7180248 0.86 MEN1 (0.37) SMN1; SMN2TDP1MEN1KMT2APKM
SCHEMBL7181691 0.84 TSPO (0.35) SMN1; SMN2TDP1ITGB1ITGA4TSPO
Lithium SCHEMBL7174732 0.84 SMN1; SMN2 (0.37) SMN1; SMN2TDP1HPGDLMNANPSR1
Lithium SCHEMBL7189981 0.84 KMT2A (0.41) SMN1; SMN2KMT2AHPGDCYP3A4L3MBTL1
Lithium SCHEMBL7180495 0.83 MEN1 (0.35) SMN1; SMN2ITGB1ITGA4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885TDP1 4234/4885ITGB1 2786/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885TDP1 4275/4885ITGB1 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.